8-K: AirSculpt Technologies Reports Declining Fourth Quarter and Full Year Fiscal 2024 Results

AirSculpt Technologies reports a decrease in revenue and case volume for both the fourth quarter and full year 2024, alongside a net loss and reduced Adjusted EBITDA.

Summary

• AirSculpt Technologies announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company experienced a challenging 2024 and is focusing on implementing strategies to deliver value for shareholders.
• Case volume for Q4 2024 decreased by 16.7% to 3,064 from 3,680 in Q4 2023.
• Revenue for Q4 2024 declined by 17.7% to $39.2 million from $47.6 million in Q4 2023.
• The net loss for the quarter was $5.0 million, compared to a net loss of $4.6 million in the same period of the previous year.
• Adjusted EBITDA for Q4 2024 was $1.9 million, a significant decrease from $10.1 million in Q4 2023.
• For the full year 2024, case volume decreased by 6.0% to 14,036 from 14,932 in 2023.
• Full-year revenue declined by 7.9% to $180.4 million from $195.9 million in the previous year.
• The net loss for the full year was $8.3 million, compared to a net loss of $4.5 million in 2023.
• Adjusted EBITDA for the full year was $20.7 million, down from $43.2 million in the previous year.
• As of December 31, 2024, the company had $8.2 million in cash and cash equivalents and no availability on its revolving credit facility.
• The company generated $11.4 million in operating cash flow for the year, compared to $24.0 million in 2023.
• AirSculpt has implemented a cost reduction program expected to deliver approximately $3 million in annualized savings and has paused de novo and new procedure room openings.
• The company expects improving trends sequentially each quarter as strategic priorities gain traction.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the declining financial performance, but there are some positive aspects such as the cost reduction program and the company's efforts to improve its strategic priorities.

Positives

• AirSculpt has implemented a cost reduction program expected to deliver approximately $3 million in annualized savings.
• The company has received additional relief from its lenders regarding future covenant compliance to enable increased investment in support of its transformation.
• The company anticipates improving trends sequentially each quarter as its strategic priorities gain traction.
• AirSculpt generated $11.4 million in operating cash flow for the twelve months ended December 31, 2024.

Negatives

• Case volume decreased by 16.7% for the fourth quarter of 2024.
• Revenue declined by 17.7% for the fourth quarter of 2024.
• The net loss for the fourth quarter was $5.0 million.
• Adjusted EBITDA decreased significantly to $1.9 million for the fourth quarter.
• Case volume decreased by 6.0% for the full year 2024.
• Revenue declined by 7.9% for the full year 2024.
• The net loss for the full year was $8.3 million.
• Adjusted EBITDA decreased significantly to $20.7 million for the full year.
• Cash and cash equivalents decreased to $8.2 million as of December 31, 2024.
• Operating cash flow decreased to $11.4 million for the full year 2024.
• The company has paused de novo and new procedure room openings.

Risks

• Failure to stabilize same-store performance could negatively impact future results.
• Inability to optimize marketing investment, go-to-market strategy, and sales process poses a risk.
• Failure to expand financing options for consumers could limit growth.
• Unsuccessful product innovations may hinder competitiveness.
• Failure to operate centers in a cost-effective manner could impact profitability.
• Increased competition in the weight loss and obesity solutions market, including the rise of weight-loss drugs, presents a challenge.
• Shortages or quality control issues with third-party manufacturers or suppliers could disrupt operations.
• Competition for surgeons may increase operating costs.
• Litigation or medical malpractice claims could result in financial losses.
• Inability to protect the confidentiality of proprietary information could harm the company's competitive advantage.
• Changes in laws governing the corporate practice of medicine or fee-splitting could impact the business model.
• Changes in regulatory and macroeconomic conditions, including inflation and recession, could affect performance.
• Business disruption from natural disasters, war, pandemic, terrorist acts, or political unrest could negatively impact operations.

Future Outlook

AirSculpt anticipates facing a tough year-over-year comparison in the first quarter but expects improving trends sequentially each quarter as its strategic priorities gain traction; the company has implemented a cost reduction program and paused de novo and new procedure room openings to increase liquidity.

Management Comments

• Yogi Jashnani, Chief Executive Officer, stated he is eager to help write the next chapter for AirSculpt and focus on setting a strategy, implementing business processes and developing a culture that delivers meaningful value for shareholders.
• Mr. Jashnani noted that his number one priority is to stabilize same center sales performance by optimizing marketing investment, improving the go-to-market strategy, implementing more robust training modules for the sales team, expanding financing options for consumers, and working on product and sales innovation.
• Mr. Jashnani believes that AirSculpt is an attractive business with a competitive moat that is ripe for disruption and that the best years lie ahead for AirSculpt and its shareholders.

Industry Context

The body contouring industry is becoming increasingly competitive, with new technologies and procedures emerging regularly; the rise of weight-loss drugs also presents a challenge to AirSculpt's business model.

Comparison to Industry Standards

• Without specific competitor data, it's difficult to provide a precise comparison, but the decline in revenue and case volume suggests AirSculpt is underperforming compared to industry growth trends.
• Companies like Sono Bello and Elite Body Sculpture are key competitors in the minimally invasive body contouring space.
• The adjusted EBITDA margin of 11.5% for the full year 2024 is significantly lower than previous years, indicating potential issues with cost management or pricing strategy compared to industry benchmarks.

Stakeholder Impact

• Shareholders will be concerned about the declining financial performance and the net loss.
• Employees may be affected by the cost reduction program and the pause in de novo openings.
• Customers may experience changes in service offerings or financing options.
• Suppliers may be impacted by the company's cost reduction efforts.
• Creditors will monitor the company's financial performance and compliance with covenants.

Next Steps

• AirSculpt will focus on stabilizing same-center sales performance.
• The company will optimize its marketing investment.
• AirSculpt will improve its go-to-market strategy.
• The company will implement more robust training modules for its sales team.
• AirSculpt will expand its financing options for consumers.
• The company will work on product and sales innovation.

Key Dates